Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin for Refractory or Relapsed PCNSL
NCT01973062Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in primary central nervous system lymphoma (PCNSL), sponsored by Case Comprehensive Cancer Center. Started Mar 2014; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT01973062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01973062.